Sens. Back PTAB Denial Rules, Drug Pricing Activists Balk
The depth of the rift over whether the U.S. Patent and Trademark Office should be denying patent challenges for reasons other than merit came fully to light, as 800 comments over...To view the full article, register now.
Already a subscriber? Click here to view full article